Flutamide
As of the edition of 20 October 2026, Flutamide is a small molecule: marketed, first approved in 1989 (US); acts on AR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- Eulexin
- First approved
- 27 January 1989 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Merck & Co.
- Registered trials
- 51, 5 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Hormones; Pregnancy and women's health; Inherited and neonatal; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AR | Androgen receptor | P10275 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 2 | 0 | 2 |
| Phase 1 | 6 | 3 | 0 | 1 |
| Phase 2 | 15 | 11 | 2 | 1 |
| Phase 3 | 23 | 16 | 5 | 1 |
| Phase 4 | 3 | 2 | 0 | 0 |
| All trials | 51 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Applicant | 1989 to now |